{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Biological Agent[C307]|Antineoplastic Biological Agent" in comments (approximate match)
Status:
US Approved Rx
(2004)
Source:
BLA125104
(2004)
Source URL:
First approved in 2004
Source:
BLA125104
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2004)
Source:
BLA125084
(2004)
Source URL:
First approved in 2004
Source:
BLA125084
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2001)
Source:
BLA103948
(2001)
Source URL:
First approved in 2001
Source:
BLA103948
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2017)
Source:
BLA761060
(2017)
Source URL:
First approved in 2000
Source:
Mylotarg
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
BLA761140
(2020)
Source URL:
First approved in 1997
Source:
BLA103705
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04225039: Phase 2 Interventional Active, not recruiting Glioblastoma
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03262935: Phase 3 Interventional Completed Metastatic Breast Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02452554: Phase 2 Interventional Completed Pleuropulmonary Blastoma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04639180: Phase 3 Interventional Active, not recruiting Hepatocellular Carcinoma (HCC)
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00679289: Phase 2 Interventional Completed Metastatic Melanoma
(2008)
Source URL:
Class:
PROTEIN
